Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model -- BMB compound significantly reduced fentanyl intake in an animal model of opioid abuse -- -- Potential to reduce continued opioid use in humans, a key treatment goal for opioid use disorder -- --...

Bright Minds Biosciences to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis VANCOUVER, British Columbia, March 10, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel...

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating -- Model is predictive for human efficacy for binge eating -- -- BMB compound reduced binge eating in rats with a clear dose range for efficacy -- -- A virtual presentation discussing the findings...

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future Growth VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of...

Bright Minds Biosciences Announces Listing on Canadian Stock Exchange VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of...